| Document |
Document Title |
|
WO/2020/090967A1 |
Provided is an expression inhibitor capable of inhibiting the expression of a fibrosis-inducing gene. The expression inhibitor according to the present invention comprises a compound represented by formula (I) or a salt thereof.
|
|
WO/2020/089619A1 |
The present invention relates to modified Factor IX polypeptides comprising a mutation at a position corresponding to position 347 of wild type immature (precursor) Factor IX, polynucleotides encoding the polypeptides, and treatments uti...
|
|
WO/2020/089908A1 |
The present invention relates to methods for treating iron deficiency in a subject comprising noninvasively determining the hemoglobin level in the subject, and providing the subject with an iron supplement accordingly.
|
|
WO/2020/092549A1 |
Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding f...
|
|
WO/2020/089443A1 |
The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected...
|
|
WO/2020/089380A1 |
The present invention relates to reversal agents, which specifically bind to the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D as described in WO2013/167669, and neutralize the therapeutic activity of this anti-FXIa antibody, as well as t...
|
|
WO/2020/087856A1 |
Provided is an application of anti-platelet thrombolysin in preparing a drug for treating anemia.
|
|
WO/2020/092898A1 |
Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.
|
|
WO/2020/085179A1 |
[Problem] The purpose of the present invention is to provide a novel technique associated with anti-obesity improvement. [Solution] The present invention relates to an anti-obesity agent comprising lactononadecapeptide (LNDP, Asn-Ile-Pro...
|
|
WO/2020/085616A1 |
The present invention relates to a novel method for preparing apixaban. The method of the present invention is economical since no expensive reagents or solvents are used therein. In addition, the method has no special conditions or comp...
|
|
WO/2020/086736A1 |
Selective inhibitors of repulsive guidance molecule C (RGMc), are described. Related methods, including methods for making, as well as therapeutic use of these inhibitors in the treatment of disorders, such as anemia, are also provided.
|
|
WO/2020/085467A1 |
The present invention pertains to a pharmaceutical composition for treating aplastic anemia, comprising romiplostim as an active ingredient. This pharmaceutical composition is characterized by: being administered subcutaneously once a we...
|
|
WO/2020/084435A1 |
The present invention discloses a novel p-toluenesulfonic acid salt and a crystalline polymorphic Form 1 of said salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-meth
ylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical compos...
|
|
WO/2020/086367A1 |
Provided are novel prodrugs of esuberaprost and pharmaceutical compositions thereof, as well as methods of making and methods of using these prodrugs.
|
|
WO/2020/086506A1 |
The present disclosure relates methods of treating myasthenia gravis with zilucoplan (RA101495), including generalized myasthenia gravis. The present dislosure also claims devices and kits for zilucoplan administration and methods of eva...
|
|
WO/2020/084599A2 |
The present invention relates to ammonium salts of partially fluorinated organic acids, represented by the general formula 1. The present invention relates also to a synthesis method of said salts as well as its use to the production of ...
|
|
WO/2020/078034A1 |
A Rivaroxaban pharmaceutical composition and a preparation method therefor. The Rivaroxaban pharmaceutical composition consists of Rivaroxaban, polyethylene glycol, a binder, a filler, a disintegrant, a surfactant and a lubricant in a ce...
|
|
WO/2020/080399A1 |
Provided are a pharmaceutical composition, which comprises, as an active ingredient, a potassium citrate and sodium citrate hydrate preparation or a sodium hydrogencarbonate preparation, etc. By administering the pharmaceutical compositi...
|
|
WO/2020/080495A1 |
The purpose of the present invention is to provide: a carboxylic acid-type lipid which can promote adhesion and coagulation of platelets without carrying a protein or peptide (e.g., GPIb or H12) which is involved in adhesion or coagulati...
|
|
WO/2020/025672A9 |
The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (...
|
|
WO/2020/075083A1 |
Dosing regimens for the treatment of coagulation disorders using anti-TFPI antibodies are provided. The methods comprises administering to a subject in need there of an initial dose of about 50 mg to 500 mg of an anti-TFPI antibody or an...
|
|
WO/2020/077184A1 |
Oxygenation constituents and finished oxygenation media, as well as methods of making oxygenation constituents and finished oxygenation media are provided. The oxygenation constituents comprise a hemoglobin preparation, and a red blood c...
|
|
WO/2020/072377A1 |
The present disclosure relates to compounds of the general formula (I) and pharmaceutical compositions containing them. The compounds are suitable as modulators of hemoglobin and thus useful in treating disorders mediated by hemoglobin s...
|
|
WO/2020/063976A1 |
Provided are a fused heterocyclic biaryl benzyl alcohol compound, a preparation method, and use. The fused heterocyclic biaryl benzyl alcohol compound is as represented by formula (IA), has good inhibition activity for a BRD enzyme, and ...
|
|
WO/2020/065252A1 |
The invention relates to Bone Morphogenetic Protein 6 (BMP6) antagonists, such as antibodies and fragments, as well as methods, uses and combinations.
|
|
WO/2020/063562A1 |
Disclosed is a fusion protein of a mutated recombinant single-chain human coagulation factor VIII (FVIII), a preparation method therefor, and a use thereof. The fusion protein sequentially comprises, from an N-terminus to a C-terminus, a...
|
|
WO/2020/062780A1 |
Disclosed in the present invention are a medicament for preventing and treating ischemic heart diseases or ischemic encephalopathy or thrombosis and use thereof. The medicament comprises indole-3-methanol and a derivative thereof or diin...
|
|
WO/2020/059812A1 |
4-(\{(4S)-1-(4-Carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)pi
perazin-1-yl]-L-prolyl\}amino)benzoic acid di(4-toluenesulfonic acid) salt or dibenzenesulfonic acid salt or a crystal form of the salt has low hygroscopicity and excellent sto...
|
|
WO/2020/060963A1 |
The disclosure provides 1, 3, 4-oxadiazole derivatives useful for stemming bleeding and for treating cancer.
|
|
WO/2020/060087A1 |
The present disclosure relates to a pharmaceutical highly efficient anti-TFPI antibody composition including an anti-TFPI antibody for treating hemophilia, in which the content of HCP in a drug substance is less than 10.0 ng/mg, and the ...
|
|
WO/2020/061465A1 |
The present disclosure provides a method of reversing ticagrelor-associated bleeding in a patient by administering an antibody or fragment thereof that binds to ticagrelor.
|
|
WO/2020/060964A1 |
The disclosure provides 1, 2, 4-oxadiazole derivatives useful for stemming bleeding and for treating cancer.
|
|
WO/2020/056430A1 |
Disclosed herein are deuterium-enriched N-Aryl pyridinone compounds, optionally in combination with one or more additional therapeutic agents, pharmaceutical compositions comprising the same, methods of preparation thereof, and methods o...
|
|
WO/2020/053857A1 |
The present invention provides compositions and methods for the treatment of skin lesions. In particular, embodiments of the invention provide topical compositions useful in the treatment and alleviation of cutaneous symptoms associated ...
|
|
WO/2020/056400A1 |
Methods and compositions for producing hemoglobin and treating alpha- thalassemia are disclosed.
|
|
WO/2020/049074A1 |
A composition comprising an iron salt of a C8 to C24 fatty acid, a citric acid ester of mono- and/or diglyceride or a mixture of citric acid esters of mono-and/or diglycerideand optionally a fatty acid or a mixture of fatty acids, and a ...
|
|
WO/2020/049786A1 |
The present invention addresses the problem of providing a combination medicine that is capable of preventing or inhibiting acquisition of resistance to a pyrimidine antimetabolite, a drug for preventing or inhibiting pyrimidine antimeta...
|
|
WO/2020/051207A2 |
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...
|
|
WO/2020/050409A1 |
Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]: wherein ring A, ring B, R1,...
|
|
WO/2020/051277A1 |
An antibody, preferably a blocking antibody, and most preferably a monoclonal antibody (mAb), specific for human endothelial cell protein C receptor (EPCR) such as mAbs JRK1494 or JRK 1535 is used to reduce or attenuate joint swelling, m...
|
|
WO/2020/047352A1 |
Provided herein are methods of treating and preventing hereditary angioedema attack in certain human patient subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 300 ...
|
|
WO/2020/045612A1 |
The present invention provides an intermittent endurance improving agent that includes one or both of aspartic acid and tyrosine.
|
|
WO/2020/045886A1 |
The present invention relates to a composition for accelerating cell proliferation, comprising an erythropoietin-derived peptide. More specifically, due to having a simpler structure than that of the existing natural human erythropoietin...
|
|
WO/2020/045940A1 |
The present invention provides a pharmaceutical composition comprising clopidogrel or pharmaceutically acceptable salts thereof; and a compound of Formula 1 or pharmaceutically acceptable salts thereof as an active ingredient. The pharma...
|
|
WO/2020/045646A1 |
The present invention provides a monoclonal antibody having high selectivity and affinity for AGEs, particularly for glyceraldehyde-derived AGEs or glycolaldehyde-derived AGEs, and an analytical method using the same. The present inventi...
|
|
WO/2020/039183A1 |
The present invention relates to polynucleotides comprising a Factor IX nucleotide sequence, wherein the Factor IX nucleotide sequence comprises a coding sequence that encodes a Factor IX protein or fragment thereof and wherein a portion...
|
|
WO/2020/039401A1 |
The present invention relates to IL-1β binding antibodies or functional fragments thereof for treating, preventing or reducing the incidence of anemia. The present invention also relates topharmaceutical combinations comprising such IL-...
|
|
WO/2020/041644A1 |
Described herein are fusion proteins that include two fragments of factor H, a fragment of factor H and an Fc domain, or a fragment of factor H, a fragment of CR2, and an Fc domain. The use of such proteins in methods of treatment for di...
|
|
WO/2020/037737A1 |
Provided is an extract of Ginkgo biloba leaves as a crude drug, prepared by alcohol extraction of Ginkgo biloba leaves, comprising ≤4.0% of rutin, ≤0.4% of quercetin, 2.6-4.8% of bilobalide, 0.1-0.5% of ginkgolide J, ≤0.5% of resid...
|
|
WO/2020/036229A1 |
Provided is a lactic acid bacterium that is highly suitable for foods, can be easily produced and is capable of increasing the level of iron in the blood to thereby ameliorate anemia. A halotolerant lactic acid bacterium capable of incre...
|
